Indegene Ltd (INDGN) is currently trading at 661.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Indegene is a digital-first life sciences commercialization company serving biopharmaceutical, biotech and medical-device businesses through enterprise commercial, medical, clinical, data and consulting solutions. It combines healthcare domain expertise, technology platforms and global delivery capabilities to help clients develop, launch, promote and scale products more efficiently across their commercialization lifecycle. Q2 FY27 revenue reached INR11,223 million, increasing 39.5% year-on-year and 5.6% sequentially in rupees. Growth was broad-based: the company served 107 active clients, clients contributing over $1 million annually increased to 59, and both top accounts and newer relationships expanded simultaneously, reducing reliance on a single growth engine. Indegene is transitioning from project-oriented content execution toward an integrated, AI-led commercialization model. Tectonic, Agentic AOR, omnichannel activation and content production are increasingly being sold together, allowing the company to participate in strategy, scientific messaging, creative development, workflow execution and measurable outcomes rather than only supplying staffing or production capacity. BioPharm’s first year inside Indegene appears strategically successful, with integration completed early, cost savings reinvested into sales expansion and proprietary physician data incorporated into the company’s AI foundation. Management believes this capability is already improving large pursuits and could become more valuable than the original acquisition’s standalone revenue contribution. Profitability remains in transition but management expects an acceleration in the second half. Q2 EBITDA margin was 16.7% despite wage inflation and lower interest income, while productivity, workforce transformation, operating leverage and a large outcome-based contract are expected to support quarterly EBITDA margins above 19% by Q4 FY27.

Over the past 52 weeks, Indegene Ltd has traded between a low of ₹414.90 and a high of ₹672.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Indegene Ltd has a market capitalization of approximately 14,846.37. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Indegene Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 36.11 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 14,846.37 Cr, Indegene Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Indegene Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Indegene Ltd is 36.11. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Indegene said the pilot developed launch positioning, physician segmentation, scientific messages and creative direction for a new molecule. Management said it used clinical data, product claims, competing molecules and therapeutic-area context to produce those outputs.

Indegene disclosed nine Q2 FY27 deal wins with annual contract values of about $1 million. The group included one contract worth more than $5 million and two valued between $3 million and $5 million. Management did not disclose the aggregate value of all nine wins.

Indegene completed the planned finance, human resources, information technology and legal transition by the end of February. The original target was the end of March, so completion was one month ahead of plan. Management said the transition did not disrupt client engagements.

Indegene said its board will consider the Q2 FY27 and first-half FY27 results on October 29, 2026, with release planned after market hours.